Research & Development
Vanda announces addition of the HETLIOZ patent in the US FDA's orange book
21 September 2018 -

Biopharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA ) reported on Thursday the listing of the HETLIOZ patent in the US Food and Drug Administration's orange book.

The company said the HETLIOZ patent, which has been assigned the number 10,071,977, is now listed in the US Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, called the Orange Book.

According to the company, the US Patent and Trademark Office issued the '977 patent on 11 September 2018 and expires in February 2035.

Previously, the HETLIOZ Orange Book listed patent with the latest expiry date was set to expire in May 2034, concluded the company.



Related Headlines